ATE319840T1 - Verfahren zur herstellung von anti-angiogene proteine; endostatin, angiostatin oder restin, mit einem expressions-system für hefe pichia - Google Patents

Verfahren zur herstellung von anti-angiogene proteine; endostatin, angiostatin oder restin, mit einem expressions-system für hefe pichia

Info

Publication number
ATE319840T1
ATE319840T1 AT98962932T AT98962932T ATE319840T1 AT E319840 T1 ATE319840 T1 AT E319840T1 AT 98962932 T AT98962932 T AT 98962932T AT 98962932 T AT98962932 T AT 98962932T AT E319840 T1 ATE319840 T1 AT E319840T1
Authority
AT
Austria
Prior art keywords
expression system
restin
endostatin
angiostatin
producing anti
Prior art date
Application number
AT98962932T
Other languages
English (en)
Inventor
Vikas P Sukhatme
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Application granted granted Critical
Publication of ATE319840T1 publication Critical patent/ATE319840T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
AT98962932T 1997-12-08 1998-12-08 Verfahren zur herstellung von anti-angiogene proteine; endostatin, angiostatin oder restin, mit einem expressions-system für hefe pichia ATE319840T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6788897P 1997-12-08 1997-12-08
US8266398P 1998-04-22 1998-04-22
US10853698P 1998-11-16 1998-11-16

Publications (1)

Publication Number Publication Date
ATE319840T1 true ATE319840T1 (de) 2006-03-15

Family

ID=27371250

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98962932T ATE319840T1 (de) 1997-12-08 1998-12-08 Verfahren zur herstellung von anti-angiogene proteine; endostatin, angiostatin oder restin, mit einem expressions-system für hefe pichia

Country Status (10)

Country Link
EP (3) EP1037985A1 (de)
JP (3) JP2001526040A (de)
KR (3) KR20010015868A (de)
CN (3) CN1322246A (de)
AT (1) ATE319840T1 (de)
AU (3) AU742866B2 (de)
CA (3) CA2312287A1 (de)
DE (1) DE69833794D1 (de)
IL (3) IL136668A0 (de)
WO (3) WO1999029856A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852691B1 (en) 1997-12-08 2005-02-08 Beth Israel Deaconess Medical Center Anti-angiogenic peptides and methods of use thereof
US6797488B1 (en) 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
JP2001526040A (ja) * 1997-12-08 2001-12-18 ベス イスラエル ディーコネス メディカル センター ピヒア酵母発現系を用いる抗血管形成タンパク質：エンドスタチン、アンジオスタチンまたはレスチンの生産方法
WO2000017240A1 (de) * 1998-09-21 2000-03-30 Haemopep Pharma Gmbh Hmw-endostatin zur hemmung des wachstums von tumoren und von gefässwucherungen und zur diagnose von gefäss- und tumorerkrankungen
IT1312077B1 (it) 1999-04-15 2002-04-04 Univ Degli Studi Milano Polipeptidi ad attivita' antiangiogenica.
JP2001031586A (ja) * 1999-07-14 2001-02-06 Sunstar Inc 動脈硬化症及び動脈硬化症に起因する疾患の予防又は治療組成物
ATE303820T1 (de) * 1999-12-30 2005-09-15 Aventis Pharma Sa Verwendung von einem für einem anti-angiogenen faktor codierenden vektor zur behandlung von vaskularisation der hornhaut
FR2803207B1 (fr) * 1999-12-30 2004-04-30 Aventis Pharma Sa Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes
AU3681601A (en) * 2000-02-10 2001-08-20 Zymogenetics Inc. Anti-angiogenic intestinal peptides, zdint5
CN1311228A (zh) * 2000-03-02 2001-09-05 上海博德基因开发有限公司 一种新的多肽——人精子特异蛋白em1,em6－48和编码这种多肽的多核苷酸
EP1666595A1 (de) 2000-10-26 2006-06-07 Beth Israel Deaconess Medical Center, Inc. P97 (GAB2) Gen, und Verfahren zu dessen Verwendung
KR100579660B1 (ko) * 2003-08-18 2006-05-15 정인식 제미니바이러스 발현시스템을 이용한 재조합 신생혈관생성억제 단백질의 제조방법
DE602004015142D1 (de) 2003-08-29 2008-08-28 Childrens Medical Center Antiangiogene peptide zur behandlung oder vorbeugung von endometriose
US7524811B2 (en) 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
ES2325344B1 (es) * 2004-11-02 2010-06-09 Univ Madrid Autonoma Inhibidores de angiogenesis multifuncionales y multivalentes.
WO2009145489A2 (ko) * 2008-04-04 2009-12-03 주식회사 프로셀제약 세포투과성 엔도스타틴 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암 조성물
JP6336389B2 (ja) * 2011-09-09 2018-06-06 チンファ ユニヴァーシティＴｓｉｎｇｈｕａ Ｕｎｉｖｅｒｓｉｔｙ Ａｔｐ結合部位に変異を有するエンドスタチン変異体
EP2628748A1 (de) 2012-02-14 2013-08-21 Szilak Laboratories Bioinformatics & Molecule-Design Ltd. Angiostatin-Chimäre und deren Verwendungen
CN104926933B (zh) * 2014-03-19 2018-09-07 北京仁和天通生物科技有限公司 Endostatin突变体、Endostatin突变体与聚乙二醇的交联物以及它们的应用
KR20180033499A (ko) 2015-06-05 2018-04-03 아이바이오, 인크. 섬유증을 치료하는데 사용하기 위한 엔도스타틴 단편 및 변이체

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
CA2188813C (en) * 1994-04-26 2010-08-03 Michael S. O'reilly Angiostatin protein, nucleic acids encoding the same and methods of detection
DE69637179T2 (de) * 1995-04-26 2008-04-10 The Children's Medical Center Corp., Boston Angiostatinfragmente und verfahren für deren verwendung
KR19990066981A (ko) * 1995-10-23 1999-08-16 윌리엄 뉴우 치료용 맥관형성억제 조성물 및 방법
AU9673998A (en) * 1997-10-01 1999-04-23 G.D. Searle & Co. Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment
WO1999026480A1 (en) * 1997-11-20 1999-06-03 Genetix Pharmaceuticals, Inc. Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases
JP2001526040A (ja) * 1997-12-08 2001-12-18 ベス イスラエル ディーコネス メディカル センター ピヒア酵母発現系を用いる抗血管形成タンパク質：エンドスタチン、アンジオスタチンまたはレスチンの生産方法

Also Published As

Publication number Publication date
CA2312287A1 (en) 1999-06-17
WO1999029878A3 (en) 1999-09-16
IL136668A0 (en) 2001-06-14
CN1284130A (zh) 2001-02-14
JP2001526031A (ja) 2001-12-18
AU753889B2 (en) 2002-10-31
CN1284134A (zh) 2001-02-14
KR20010015867A (ko) 2001-02-26
WO1999029855A1 (en) 1999-06-17
CA2313251A1 (en) 1999-06-17
AU749904B2 (en) 2002-07-04
AU742866B2 (en) 2002-01-17
EP1037985A1 (de) 2000-09-27
IL136665A0 (en) 2001-06-14
CN1322246A (zh) 2001-11-14
CA2313705A1 (en) 1999-06-17
DE69833794D1 (de) 2006-05-04
AU1808899A (en) 1999-06-28
JP2002503449A (ja) 2002-02-05
WO1999029878A2 (en) 1999-06-17
IL136667A0 (en) 2001-06-14
KR20010015869A (ko) 2001-02-26
AU1718099A (en) 1999-06-28
KR20010015868A (ko) 2001-02-26
EP1038011B1 (de) 2006-03-08
EP1037983A1 (de) 2000-09-27
JP2001526040A (ja) 2001-12-18
WO1999029856A1 (en) 1999-06-17
AU1806599A (en) 1999-06-28
EP1038011A2 (de) 2000-09-27

Similar Documents

Publication Publication Date Title
DE69833794D1 (de) Verfahren zur herstellung von anti-angiogene proteine; endostatin, angiostatin oder restin, mit einem expressions-system für hefe pichia
DE60333201D1 (de) Verfahren zur herstellung von proteinen
DK0839006T3 (da) Fremgangsmåde til stabilisering af proteiner i et surt miljø med et højester-pectin
ATE435292T1 (de) Thermophiles expressionssystem in pilzen
WO1998021341A3 (en) Method for the recombinant production of 1,3-propanediol
FI963266A (fi) Menetelmä lipolyyttisen entsyymin muunnoksen valmistamiseksi
PT1204738E (pt) Processo para a diminuicao da formacao de espuma durante a cultura de um microrganismo
ATE203270T1 (de) Verfahren für die herstellung von proteinen
DE69711629D1 (de) Verfahren zur herstellung von polyol-fettsäure-polyestern unter verwendung atmosphärischen oder überatmosphärischen drucks
DE3585953D1 (de) Dna-fragmente, expressionsvektoren, proteine, wirte und verfahren zur herstellung der proteine.
DE60011390D1 (de) Verfahren und vorrichtung zur identifikation oder karakterisierung von polypeptiden
DE69920747D1 (de) Methode zur herstellung von rekombinanten zellen
DE59701603D1 (de) Verfahren zur herstellung von organisch modifizierten aerogelen
DE3860864D1 (de) Optisch aktive alpha-aminoaldehyde, verfahren zu ihrer herstellung und ihre verwendung zur stereoselektiven herstellung optisch aktiver beta-aminoalkohole.
DE59710925D1 (de) Verfahren zur herstellung von organisch modifizierten aerogelen
DE68917154D1 (de) C-terminus-amidierungsenzym-zusammensetzung, verfahren zur herstellung und verwendung.
DE69534133D1 (de) Herstellung von nisin-varianten
DE58905117D1 (de) Verfahren zur herstellung von 4-chlor-2,5-dimethoxyanilin.
DE3575743D1 (de) Verfahren zur gewinnung von phenylalanin-dehydrogenase enthaltenden mikroorganismen und deren verwendung zur herstellung von l-alpha-aminosaeuren.
DE59606567D1 (de) Neuer Mikroorganismus, dessen Verwendung und Verfahren zur Herstellung von L-Alpha-Aminosäuren
DE69013446D1 (de) Alkalische Pullulanase, Mikroorganismus der sie produziert und Verfahren zur Herstellung dieses Enzyms.
DE69613811D1 (de) Methode und System zur Erzeugung und Verwendung von Brenngasen, insbesondere Gasen hergestellt aus Biomassen und Abfall
ATE522604T1 (de) Verfahren zur herstellung von proteinen durch elektropulsierung
DE60032585D1 (de) Hyphenwachstum in pilzen
DE3671603D1 (de) Verfahren zur zucht von babesia canis, verwendung zur herstellung von antigenen und impfstoffen und antigene und impfstoffe gegen piroplasmose.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties